These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 19191903)

  • 1. Regulation of different inflammatory diseases by impacting the mevalonate pathway.
    Zeiser R; Maas K; Youssef S; Dürr C; Steinman L; Negrin RS
    Immunology; 2009 May; 127(1):18-25. PubMed ID: 19191903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune modulatory effects of statins.
    Zeiser R
    Immunology; 2018 May; 154(1):69-75. PubMed ID: 29392731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The beneficial effects of statins in autoimmune disease therapy.
    Marai I; Shoenfeld Y
    Drug News Perspect; 2007 Apr; 20(3):165-9. PubMed ID: 17520093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statins: pros and cons.
    Pinal-Fernandez I; Casal-Dominguez M; Mammen AL
    Med Clin (Barc); 2018 May; 150(10):398-402. PubMed ID: 29292104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statins and autoimmune diseases.
    Gurevich VS; Shovman O; Slutzky L; Meroni PL; Shoenfeld Y
    Autoimmun Rev; 2005 Mar; 4(3):123-9. PubMed ID: 15823497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mevalonate signaling, COPD and cancer: the statins and beyond.
    Hopkins RJ; Young RP
    J Investig Med; 2019 Apr; 67(4):711-714. PubMed ID: 30787037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulatory effects of statins and autoimmune rheumatic diseases: novel intracellular mechanism involved.
    Tristano AG; Fuller K
    Int Immunopharmacol; 2006 Dec; 6(12):1833-46. PubMed ID: 17052674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Basic and Clinical Observations of Mevalonate Depletion on the Mevalonate Signaling Pathway.
    Muller AL; Freed DH
    Curr Mol Pharmacol; 2017; 10(1):6-12. PubMed ID: 26758946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of statins on MHC class I expression.
    Singh P; Kohr D; Kaps M; Blaes F
    Ann N Y Acad Sci; 2009 Sep; 1173():746-51. PubMed ID: 19758224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulator activity of 3-hydroxy-3-methilglutaryl-CoA inhibitors.
    Smaldone C; Brugaletta S; Pazzano V; Liuzzo G
    Cardiovasc Hematol Agents Med Chem; 2009 Oct; 7(4):279-94. PubMed ID: 19663791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statins and autoimmunity: State-of-the-art.
    Dehnavi S; Sohrabi N; Sadeghi M; Lansberg P; Banach M; Al-Rasadi K; Johnston TP; Sahebkar A
    Pharmacol Ther; 2020 Oct; 214():107614. PubMed ID: 32592715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel aspects of mevalonate pathway inhibitors as antitumor agents.
    Thurnher M; Nussbaumer O; Gruenbacher G
    Clin Cancer Res; 2012 Jul; 18(13):3524-31. PubMed ID: 22529099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translating the effects of statins: from redox regulation to suppression of vascular wall inflammation.
    Antonopoulos AS; Margaritis M; Shirodaria C; Antoniades C
    Thromb Haemost; 2012 Nov; 108(5):840-8. PubMed ID: 22872079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy.
    Danesh FR; Kanwar YS
    FASEB J; 2004 May; 18(7):805-15. PubMed ID: 15117885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mevalonate Cascade and Neurodevelopmental and Neurodegenerative Diseases: Future Targets for Therapeutic Application.
    Jiao X; Ashtari N; Rahimi-Balaei M; Chen QM; Badbezanchi I; Shojaei S; Marzban A; Mirzaei N; Chung S; Guan T; Li J; Vriend J; Mehr SE; Kong J; Marzban H
    Curr Mol Pharmacol; 2017; 10(2):115-140. PubMed ID: 26758948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statins and protein prenylation in cancer cell biology and therapy.
    Garcia-Ruiz C; Morales A; Fernandez-Checa JC
    Anticancer Agents Med Chem; 2012 May; 12(4):303-15. PubMed ID: 22413970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statins: from cholesterol-lowering drugs to novel immunomodulators for the treatment of Th17-mediated autoimmune diseases.
    Ulivieri C; Baldari CT
    Pharmacol Res; 2014 Oct; 88():41-52. PubMed ID: 24657239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current insights into pathogenesis of Parkinson's disease: Approach to mevalonate pathway and protective role of statins.
    Saeedi Saravi SS; Saeedi Saravi SS; Khoshbin K; Dehpour AR
    Biomed Pharmacother; 2017 Jun; 90():724-730. PubMed ID: 28419968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the Mevalonate Pathway for Treating Esophageal Cancer.
    Wong JVS; Fatehi Hassanabad A
    J Gastrointest Cancer; 2021 Jun; 52(2):819-821. PubMed ID: 33931828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases?
    McCarey DW; Sattar N; McInnes IB
    Arthritis Res Ther; 2005; 7(2):55-61. PubMed ID: 15743490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.